Background-Racial differences in long-term survival after heart transplant (HT) are well known. We sought to assess racial/ethnic differences in wait-list outcomes among patients listed for HT in the United States in the current era. 
limination of racial and socioeconomic disparities in health is a national priority in the United States. 1 Racial gaps in cardiovascular care have been described in utilization of coronary revascularization and coronary artery bypass surgery, in adaptation of newer technologies such as drugeluting stents and cardiac resynchronization therapy, and in utilization of evidence-based medicines for primary and secondary prevention. [2] [3] [4] [5] [6] [7] [8] [9] Quality-improvement initiatives to promote provider adherence with evidence-based practices have not only led to improvement in performance measures, but also to narrowing of racial gaps. 10 
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Racial differences in long-term survival after heart transplant (HT) are well -known with several studies demonstrating shorter graft life in black HT recipients. [11] [12] [13] However, there is limited information regarding racial/ethnic differences in mortality among those awaiting a HT 14 and none in the current era. With a gradual change in US demographics, minorities represent a growing proportion of US population and may be expected to represent a higher percentage of HT candidates over time. 5, 12 It is therefore important to know if there are racial/ethnic differences in wait-list mortality in the United States in the current era. Furthermore, because the sicker patients on the HT wait-list may also be at higher risk of early posttransplant mortality, analysis of early posttransplant mortality may provide additional insights into wait-list outcomes.
Therefore, we sought to compare the risk of wait-list and early posttransplant mortality among major racial/ethnic groups in the United States in the current era. The specific objectives of this study were (1) to compare baseline characteristics between white, black, and Hispanic patients listed for a HT in the United States, (2) to compare wait-list mortality between these racial/ethnic groups, and (3) to compare early posttransplant mortality between HT recipients in the 3 groups. We defined the current era as the era of current heart allocation policy in the United States (implemented on July 12, 2006) , which allowed broader regional sharing of donor hearts with sicker patients before their allocation to less sick local HT candidates. [15] [16] [17] 
Methods

Study Population
All subjects Ն18 years of age who were listed for their first HT in the United States between July 12, 2006 and September 30, 2010 were identified in the Organ Procurement and Transplantation Network (OPTN) database. The OPTN database includes data on all patients listed for a HT in the United States submitted by their transplant centers. These data are provided to investigators as deidentified data. The Health Resources and Services Administration, US Department of Health and Human Services, provides oversight to the activities of the OPTN contractor, the United Network of Organ Sharing (UNOS). We excluded patients who were listed for a heart retransplantation or multiorgan transplantation.
Study Design and Definitions
We compared baseline characteristics and outcomes between white, black, and Hispanic patients listed for a primary HT during the study period. The primary end point was a composite of death on the wait-list or becoming too sick for a transplant (removal from the list owing to clinical deterioration) within 1 year of listing. Patients who received a HT or were removed from the wait-list because of recovery or other reasons were censored. A secondary end point was posttransplant in-hospital mortality in those who received a HT. For analysis of wait-list outcomes, patients were followed from the time of listing until death, HT, removal from the list, the day of last observation on March 31, 2011, or for 1 year. Patients who received a HT were followed until hospital discharge, death, or the day of last observation.
Demographic and clinical variables were defined at the time of listing for wait-list outcomes and at the time of transplant for posttransplant outcomes. Race, a mandatory variable in the OPTN database, was reported by the transplant centers as one of the following: white, black, Hispanic/Latino, Asian, American Indian/ Alaska Native, Native Hawaiian/Pacific Islander, Multiracial and Other. Ethnicity, also a mandatory variable, was reported as Hispanic or non-Hispanic. Because of the small sample size of minorities other than black and Hispanic groups (3.5% of all HT candidates), these patients were not analyzed.
Renal function was analyzed (1) as a categorical variable (plasma creatinine Ͼ1.5 mg/dL) and (2) as estimated glomerular filtration rate with use of the Modification of Diet in Renal Disease formula. 18, 19 To assess whether the relationship between race/ethnicity and patient outcome was related to center volume, we divided listing centers into 3 categories based on center volume: low volume (nϭ65, those with Ͻ72 patients listed for HT during the 4-year study period), medium volume (nϭ51, those with 72-179 patients listed), and high volume (nϭ13, Ͼ179 patients listed) centers. The number of patients chosen to define centers as low-, medium-, and highvolume canters was empirical and derived from the distribution of listed patients among 129 US centers during the study period as follows: Ͻ50th percentile, 50th to 90th percentile, and Ͼ90th percentile for low-, medium-, and high-volume centers, respectively.
None of the subjects had any missing data for the following variables: age, sex, race/ethnicity, cardiac diagnosis, blood type, hemodynamic support (intra-aortic balloon pump, inotrope support, ventilator, type of mechanical support), medical insurance (Medicaid), UNOS listing status, dialysis, and the dates of listing, transplant, death, or removal from the wait-list. For patients with missing data on other variables, we created indicator variables "variable not reported" for each such variable to allow these patients to contribute their available risk factors in multivariable models.
Statistical Analysis
Summary data are presented as median (25th, 75th percentile) or number (percentage). Baseline characteristics between racial/ethnic groups were compared by use of the 2 test for categorical and the Kruskal-Wallis test for continuous variables. The primary end point (death on the wait-list or removal from the list because of clinical deterioration) in each group was assessed by use of competingoutcomes analysis. 20, 21 A multivariable Cox proportional hazards model was developed using a forward selection procedure retaining variables significant at the 0.10 level based on a likelihood ratio test; all variables in Table 1 were considered. To examine the relationship between center volume and wait-list mortality by use of the Cox model, we accounted for the lack of independence among patients treated at the same center (clustering) by using a frailty model. Finally, we assessed the association of race/ethnicity with wait-list mortality in prespecified subgroups to evaluate the consistency of this relationship and to assess the interaction of race/ethnicity with other variables. A multivariable logistic regression model was developed to evaluate racial/ethnic differences in posttransplant in-hospital mortality adjusted for baseline risk factors. The distributions of causes of wait-list and posttransplant in-hospital mortality by race/ethnicity were compared by use of the 2 test. Data were analyzed with the use of SAS statistical software version 9.3 (SAS Institute Inc, Cary, NC). All statistical tests were 2-sided, and a probability value of Ͻ0.05 was used to define statistical significance.
Results
Study Population
During the study period, 10 754 patients Ն18 years of age were listed in the United States for their primary HT. Of these, 377 patients (3.5%) were from racial/ethnic groups other than those in the study and were not analyzed. The remaining 10 377 patients formed the analytic cohort. Of these, 7381 (71%) were white, 2205 (21%) were black, and 791 (8%) were Hispanic. In the OPTN database, race and ethnicity are reported as 2 distinct variables (see Methods); however, for all Hispanic patients in the study cohort, race and ethnicity variables were reported to be concordant (identical). Therefore, all white patients in this analysis are non-Hispanic white, and all black patients are non-Hispanic black. Table 1 summarizes baseline characteristics in white, black, and Hispanic patients listed for a HT during the study period. Black and Hispanic patients were younger than white patients and were more likely to have blood type O (black 49%, Hispanic 52% versus white 42%, PϽ0.001), dilated cardiomyopathy (71%, 55% versus 39%, PϽ0.001), pulmonary artery wedge pressure Ͼ20 mm Hg (55%, 54% versus 47%, PϽ0.001), and Medicaid insurance (23%, 26% versus 10%, PϽ0.001). Black and Hispanic patients were also more likely to be listed at low-volume centers (21%, 24% versus 16%, PϽ0.001; Table 1 ).
Black and Hispanic patients were more likely to be listed with higher urgency as status 1A/1B 17 (black 69%, Hispanic 65% versus white 54%, PϽ0.001) and were more likely to be supported on intravenous inotropes at listing (39%, 40% versus 30%, PϽ0.001). Hispanic patients were less likely to be supported on a left ventricular assist device [LVAD] (white 13%, black 15% versus Hispanic 10%) or any mechanical support (white 17%, black 18% versus Hispanic 14%) at listing. 
Wait-List Mortality
Overall, 1137 (11.0%) patients reached the primary end point (708 died on the wait-list, 429 were removed because of clinical deterioration) within 1 year of listing. Figure 1 illustrates competing outcomes for white (1A), black (1B), and Hispanic (1C) patients listed for a HT and the cumulative percentage of patients in the 3 groups who died on the wait-list or became too sick for a transplant (1D). Overall, 10.5% of white, 11.6% of black, and 13.4% of Hispanic candidates on the HT wait-list reached the primary end point. The incidence rate of dying on the wait-list or becoming too sick for a transplant was 23 of 100 patient-years in white patients, 26 of 100 patient-years in black patients, and 36 of 100 patient-years in Hispanic patients. In univariate analysis, Hispanic patients (hazard ratio [HR] 1.51, 95% CI 1.23, 1.85) were at a higher risk of death on the wait-list or becoming too sick for a transplant in comparison with white patients. There was also a trend toward a higher risk in black patients (HR 1.13, 95% CI 0.98, 1.30). Other factors associated with the primary end point were older age, restrictive cardiomyopathy, pulmonary capillary wedge pressure Ͼ20 mm Hg, listing status 1A or 1B, inotrope support, ventilator support, intra-aortic balloon pump, mechanical support (temporary or durable), diabetes and renal dysfunction (online-only Data Supplement Table I ). Table 2 illustrates the association of race/ethnicity with wait-list mortality (or becoming too sick for a transplant) in a multivariable model. After controlling for age, diagnosis, listing status, pulmonary artery wedge pressure, support variables (inotropes, ventilator, mechanical support, intra-aortic balloon pump, implantable cardioverter defibrillator [ICD]), and renal function, Hispanic (HR, 1.51; 95% CI, 1.23, 1.85) patients were at 51% higher risk of death on the wait-list or becoming too sick for a transplant in comparison with white patients; however, the risk for black patients was not increased (HR, 1.13; 95% CI, 0.97, 1.31). Being supported on a continuousflow LVAD (HR, 0.51; 95% CI, 0.40, 0.66) or having an ICD (HR, 0.84; 95% CI, 0.73, 0.97) was protective in adjusted analysis. These findings remained unchanged after further adjustment for blood type, education (college degree), and medical insurance. There was a significant regional variability among the 11 UNOS regions in risk of wait-list mortality in adjusted analysis (HR range, 1.0 -1.63; Pϭ0.02, adjusted for all covariates in Table 2 ). However, the association between race/ethnicity and the wait-list end point remained unchanged after adjusting for region of listing or for center volume. Blood type (HR, 1.01; 95% CI, 0.88, 1.15 for type O; HR, 0.97; 95% CI, 0.79, 1.19 for blood type B, reference group, type A; adjusted analysis), education, medical insurance, and listing-center volume were not associated with wait-list mortality. Finally, there was no significant interaction between race and any of the risk factors in Table 2 for wait-list outcome, and subgroup analyses (data not presented) demonstrated similar risk among black and Hispanic subgroups. Data are presented as median (25th, 75th percentile) or number (percent). CMP indicates cardiomyopathy; BMI, body mass index; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygenation; ICD, implantable cardioverter defibrillator; BIVAD, biventricular assist device; LVAD, left ventricular assist device; IV, intravenous; and GFR, glomerular filtration rate.
Early Posttransplant Mortality
*Includes patients on dialysis.
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(interquartile range 19, 147 days) in Hispanic patients on the wait-list (PϽ0.001). Among 6626 study subjects who received a HT and where discharge status was known, 6273 (94.7%) subjects were discharged from the hospital before the last day of the study and 353 (5.3%) died before hospital discharge (see online-only Data Supplement Table II for clinical variables at transplant). Posttransplant in-hospital mortality was 5.4% in white, 5.9% in black, and 3.6% in Hispanic HT recipients. Hispanic HT recipients were less likely to be supported on an LVAD (white 25%, black 27% versus Hispanic 20%) or any mechanical support (white 31%, black 33% versus Hispanic 26%) in comparison with other groups at the time of transplant. In analysis adjusted for age, cardiac diagnosis, hemodynamic support, end-organ function, and donor factors (Table 3) , black recipients were at higher risk of posttransplant in-hospital mortality (adjusted odds ratio, 1.53; 95% CI, 1.15, 2.03) in comparison with white recipients. The risk in Hispanic recipients was similar to white recipients (adjusted odds ratio, 0.78, 95% CI, 0.48, 1.29). These findings remained unchanged after further adjusting for patient medical insurance and blood type. There were no regional differences among the 11 UNOS regions for early posttransplant mortality in univariate or adjusted analysis. Furthermore, adding regions to the adjusted analysis did not change the association of race/ethnicity with posttransplant mortality.
Causes of Wait-List and Posttransplant Deaths
The primary cause of death among racial/ethnic groups who reached the wait-list or posttransplant mortality end point is summarized in Table 4 . Cardiovascular deaths (26%), deaths due to multiorgan failure (14%), and removal from the list because of deterioration (38%) were the 3 major contributors to wait-list end point. Multiorgan failure appeared to be a more frequent cause of wait-list death among Hispanic (20%) in compared with white (15%) or black (8%) patients. Among patients who died posttransplant before hospital discharge, rejection deaths were rare (2%), whereas deaths attributed to graft failure not due to rejection (28%), infection (21%), and multiorgan failure (26%) were more common. Graft failure was a more frequent cause among black patients who died (35%) in comparison with white (26%) or Hispanic patients (21%), but the differences in distribution of cause of death did not reach statistical significance (Table 4) .
Discussion
There are 3 major findings of this study. First, black and Hispanic patients listed for a HT are younger, are more likely to have dilated cardiomyopathy, and are listed with higher urgency (listing status 1A/1B) 17 in comparison with white patients. Second, Hispanic patients are at 50% higher risk of dying on the wait-list or becoming too sick for a transplant in comparison with white patients after adjusting for patient factors such as cardiac diagnosis, hemodynamic support, and end-organ function. Notably, the higher risk is present despite a shorter wait-time for receiving a HT in Hispanic patients. There is no increase in early posttransplant mortality among Hispanic patients who receive a HT. Finally, although the risk of wait-list mortality is not increased in black patients (versus white patients), those who receive a HT are at 50% higher risk of early posttransplant mortality adjusted for patient factors. An important clinical goal when listing a patient for HT is to keep the patient alive until HT followed by posttransplant recovery to hospital discharge. Both black and Hispanic patients appear to be falling short of achieving this goal in the current era. Although the 2 groups have some similarities in clinical features at the time of listing for HT, their risk of death while awaiting HT and in the posttransplant period is not similar. Understanding the mechanisms for these findings requires further investigation, because the 2 groups may be best served by a different approach for improving their outcomes. Several studies have assessed racial differences in longterm survival among HT recipients and have attributed a higher rate of graft loss in black recipients to immune-related mechanisms. [11] [12] [13] This is the first study to focus on racial/ ethnic differences in wait-list outcomes. The findings were somewhat unexpected in light of previous observations from several unrelated sources. First, among those listed status 1A during 1990 to 2005, white patients were at higher risk of 60-day wait-list mortality in comparison with other groups. 14 Second, a pediatric analysis of HT wait-list mortality during 2005 to 2009 in the United States found no differences among racial/ethnic groups because the racial gaps present in earlier eras disappeared. 22, 23 Third, black and Hispanic patients hospitalized for heart failure have been shown to have lower hospital mortality despite their worse cardiovascular risk profile. 24 -26 Finally, we had speculated that recent advances in the management of advanced heart failure (in particular, increased utilization of ventricular assist device (VAD) support to prevent end-organ dysfunction and of ICD to prevent arrhythmic deaths) and the new heart allocation policy (directing donor hearts to sicker patients on the wait-list) would both help to narrow any racial gaps in wait-list outcomes that may have previously existed. Although a recent analysis suggested that the decline in HT wait-list mortality associated with the new allocation algorithm may have benefited white candidates but not minorities, 27 our working hypothesis was that of similar wait-list outcomes among major racial/ethnic groups.
Our analysis also demonstrates that continuous-flow LVAD support and ICD are associated with longer time to the composite wait-list end point. A recent analysis of continuous-flow LVAD used as a bridge to HT reported similar findings with 91% 6-month survival in such patients. 28 It is worth pointing out that ICD utilization was similar among racial/ethnic groups in our analysis. We found HR indicates hazard ration; CMP, cardiomyopathy; PCWP, pulmonary capillary wedge pressure; IABP, intra-aortic balloon pump; ICD, implantable cardioverter defibrillator; BIVAD, biventricular assist device; and LVAD, left ventricular assist device. 
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Race/Ethnicity and Wait-List Outcomesit intriguing, however, that, despite a higher likelihood of being listed more urgently (status 1A/1B) in comparison with white patients, Hispanic patients were less likely to be supported on an LVAD (or any mechanical support) at the time of listing (or at the time of transplant) and instead were more likely to be managed with intravenous inotropes. Whether a lower utilization rate of LVAD/mechanical support in Hispanic patients was due to clinical factors that made these patients less suitable VAD candidates, reflects patient preferences against use of VAD therapies, or reflects disparities in care cannot be assessed by using OPTN data. Irrespective of the cause, the protective effect of continuousflow LVAD in the overall cohort suggests that VADs may be currently underutilized in Hispanic patients, 29 and a higher utilization in these patients may help to improve their outcome on the HT wait-list. The Institute of Medicine has defined disparities as racial or ethnic differences in health that are not due to differences in access, clinical needs, preferences, or appropriateness of intervention. 1 Thus, disparities are differences that cannot be explained by the biology of the disease. 5 Although we adjusted for all available clinical variables, worse outcomes in Hispanic and black patients could still be due to their residual clinical risk related to access such as a late presentation for HT evaluation or a more rapid progression of heart failure. 5, 24 However, socioeconomic differences among racial/ethnic groups, including among HT recipients, are well known 30 -32 and were also present in this cohort. For example, black and Hispanic patients were less likely to have a college degree, were less likely to be working for income, and were more likely to have Medicaid insurance, although these factors were not associated with the outcomes assessed.
The risk factors for wait-list mortality (Table 2 ) and posttransplant mortality (Table 3 ) have some overlap, and the sicker patients tend to fare poorly both while on the wait-list and in the posttransplant period. However, the relative risk associated with individual risk factors in the 2 periods is different and may account for the difference between Hispanic and black patients in their risk of death while awaiting HT and in the posttransplant period. Although we are unable to tease out the proportion of residual risk that may be attributed to biological and social factors, the magnitude of the observed differences appears to be clinically important. Awareness of outcome differences related to a risk factor (such as race/ethnicity) is an important first step in ameliorating the risk. Limited awareness of racial disparities in cardiovascular care among cardiologists has been reported previously. 33 In contrast, several studies have demonstrated narrowing of racial gaps in performance measures after implementation of quality-improvement initiatives such as the American Heart Association-Get with the Guidelines Program, including in patients hospitalized with heart failure. 26, 34, 35 Thus, once racial differences in outcomes are identified and measures taken to improve quality, narrowing of racial gaps in performance measures tend to follow. The creation of the coalition to reduce racial and ethnic disparities in cardiovascular disease outcomes (CREDO) by the American College of Cardiology reflects the community's commitment to narrow and eliminate racial/ethnic gaps in cardiovascular health. The results of our study underscore a need for quality initiatives in advanced heart failure, specifically in patients being evaluated for VAD therapy or HT with performance measures stratified by race to further understand and eliminate racial gaps described in this analysis.
There are several limitations of this study. First, this was a retrospective analysis of a national database with potential variability in quality control of submitted data among HT centers. However, because these data are used by UNOS for real-time organ allocation, are periodically audited by the UNOS staff for their accuracy, and are used by the Scientific Registry of Transplant Recipients to report center performance, certain safeguards to data quality are to be expected. Second, race and ethnicity were analyzed as reported by the centers and may not have been self-reported by patients, creating the possibility that some patients may have been misclassified. Third, the sensitization status of patients was available only at the time of HT and not at the time of listing. We were unable to investigate whether racial groups differed with respect to sensitization status at listing and whether that contributed to racial differences in wait-list mortality. Fourth, we could not evaluate socioeconomic factors in more detail because the database had only limited patient-level information. Finally, our analysis is limited to patients in advanced heart failure who are already listed for transplant; no clinical data before HT listing were available. Therefore, we could not assess health care access, heart failure presentation, criteria for VAD implantation, and criteria for HT listing which may all be important in understanding the mechanisms for racial/ethnic differences in outcomes.
In conclusion, Hispanic patients listed for a HT in the United States appear to be at higher risk of dying on the wait-list or becoming too sick for a transplant in comparison with white patients. Increased heart failure severity at listing and lower VAD utilization rates may contribute to this finding. Black patients are not at higher risk of wait-list mortality but have higher early posttransplant mortality. These gaps in wait-list and posttransplant outcomes among racial/ethnic groups merit further investigation. Date are presented as number (percent). *Includes patients who were removed from the list due to deterioration.
